Catheter Precision Announces Accelerated Momentum for LockeT Device with New Hospital Approvals and Strong Q1 Adoption Outlook

Rhea-AI Summary

Catheter Precision (NYSE American: VTAK) announced expanded hospital evaluations and approvals for its LockeT suture retention device and reports its highest recorded January revenue. The company highlighted new U.S. high-volume center evaluations, international market entries including CE Mark activity, and an expected strong Q1 2026 adoption driven by workflow and cost benefits.

Management named several hospitals undergoing evaluations and cited faster staff onboarding, same-day discharge potential, and continued European penetration as adoption drivers.

News Market Reaction

+1.63%

4 alerts

+1.63% News Effect

-12.1% Trough Tracked

+$50K Valuation Impact

$3M Market Cap

1.1x Rel. Volume

On the day this news was published, VTAK gained 1.63%, reflecting a mild positive market reaction. Argus tracked a trough of -12.1% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $50K to the company's valuation, bringing the market cap to $3M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $1.89 Vol: Volume 18,139 is at 0.79x...

normal vol

$1.89 Last Close

Volume Volume 18,139 is at 0.79x the 20-day average of 22,991, suggesting no pre‑news accumulation. normal

Technical Shares at $1.84 are trading below the $3.32 200-day MA and about 88% under the 52‑week high.

Peers on Argus

Sector peers show mixed moves, with NUWE up 1.57% while BBLG, BJDX, VERO and NAO...

Sector peers show mixed moves, with NUWE up 1.57% while BBLG, BJDX, VERO and NAOV are down between about 1.95% and 3.63%. With VTAK down 2.13% pre‑news and no peers in the momentum scanner, the setup appears stock‑specific rather than a coordinated sector rotation.

Historical Context

5 past events · Latest: Jan 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 22	LockeT German order	Positive	+10.4%	First LockeT purchase order in Germany, citing large EP market opportunity.
Jan 20	VIVO order Slovenia	Positive	-1.9%	New VIVO order expanding footprint to 15 countries via distribution partnerships.
Dec 18	LockeT Ireland expansion	Positive	+0.9%	Multi‑year LockeT commitment at major Irish EP center after rapid onboarding.
Dec 18	VIVO Hungary tender	Positive	+13.3%	Multi‑year VIVO tender in Hungary, supporting broader Central/Eastern Europe push.
Dec 01	LockeT Swiss launch	Positive	-3.3%	Commercial launch of LockeT in Switzerland with positive initial clinical feedback.

Pattern Detected

Commercial expansion news for LockeT and VIVO has often led to positive but inconsistent price reactions, with both rallies and selloffs following seemingly constructive updates.

Recent Company History

Over the past several months, Catheter Precision has focused on commercial expansion for LockeT and VIVO. Updates included LockeT’s first German order on Jan 22, 2026 and earlier launches in Switzerland and Ireland, plus multi‑year VIVO tenders in Hungary and other European markets. Price reactions ranged from a 13.33% move higher on a VIVO tender to a -3.31% drop on a Swiss LockeT launch, showing that positive commercial milestones have produced mixed trading responses. Today’s Q1 2026 adoption commentary continues that commercialization narrative.

Market Pulse Summary

This announcement highlights continued momentum for LockeT, with new U.S. high‑volume centers evalua...

Analysis

This announcement highlights continued momentum for LockeT, with new U.S. high‑volume centers evaluating the device and international adoption building on prior CE Mark clearance. Recent history shows a series of commercial wins for LockeT and VIVO across Europe, yet filings also flagged ongoing losses and going‑concern risk. Investors may watch how many Q1 2026 evaluations convert to long‑term agreements and how commercialization progress interacts with the company’s broader financing needs.

Key Terms

electrophysiology, suture retention device, same-day discharge, CE Mark

4 terms

electrophysiology medical

"a medical device company specializing in advanced electrophysiology solutions, today announced"

The study and measurement of the electrical signals that control cells and tissues, most commonly used to diagnose and treat heart rhythm problems and to test how nerves and muscles communicate. Investors care because electrophysiology drives products, procedures and drugs—like monitoring systems, catheter tools and implants—that can alter a medical device or drug maker’s sales, regulatory approvals and clinical trial outcomes; think of it as checking and fixing the wiring that makes the body run.

suture retention device medical

"hospital evaluations and approvals for its LockeT suture retention device. As the company"

A suture retention device is a small medical tool used during wound closure to hold stitches in place and spread the force of the stitch over a larger area of skin or tissue, similar to how a button or washer prevents a rope from cutting through fabric. For investors, these devices matter because they can reduce wound complications, shorten surgery or recovery time, and lower follow-up costs—factors that affect hospital adoption, reimbursement, and market demand.

same-day discharge medical

"By facilitating same-day discharge and reducing post-procedural bed rest, LockeT offers"

Same-day discharge means a patient who undergoes a medical procedure is released to go home on the same calendar day rather than staying overnight in the hospital. For investors, it signals lower per-patient costs, faster bed turnover and potentially higher procedure volumes—like a restaurant turning tables more quickly—while also affecting reimbursement, facility investment and perceived quality of care, which can influence revenue and margins.

CE Mark regulatory

"International Expansion: Building on its CE Mark approval, the company continues to"

A CE mark is a regulatory stamp placed on products to show they meet the European Union’s basic safety, health and environmental rules and can be sold in the European Economic Area. For investors it matters because the mark unlocks market access, affects how quickly a product can generate revenue, and signals regulatory risk and potential compliance costs—think of it as a passport that lets a product enter a large market.

AI-generated analysis. Not financial advice.

FORT MILL, S.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a medical device company specializing in advanced electrophysiology solutions, today announced a surge in hospital evaluations and approvals for its LockeT suture retention device. As the company enters the first quarter of 2026, it reports significant progress in domestic and international product adoption, driven by successful clinical outcomes and the device's ability to streamline hospital workflows.

Following its highest recorded revenue for the month of January, and following its recent entry into several international markets, Catheter Precision has secured approval for evaluations at several additional influential high-volume centers throughout the Unites States. These evaluations are a critical precursor to long-term purchasing agreements, allowing clinical teams to validate LockeT’s efficacy and additional adoption at affiliated hospitals within a network.

"The initial feedback from our newest hospital partners confirms that LockeT addresses a critical need for efficient, cost-effective wound closure," said David Jenkins, CEO of Catheter Precision. "We are entering 2026 with a strong pipeline of evaluations that we expect will transition into permanent adoption, further solidifying our position in the global electrophysiology market. Those hospitals where we have completed evaluations, or shortly expect to complete evaluations, are among hospitals of the highest repute, including John’s Hopkins, University of Michigan, Beth Israel in Boston, Northside hospitals in Atlanta, and Scripps in Southern California."

The company anticipates robust product adoption throughout Q1 2026, supported by:

• Operational Efficiency: LockeT's intuitive design has demonstrated rapid staff onboarding, notably training system wide collaborating staff members in several days at major institutions.
• Cost-Effective Innovation: By facilitating same-day discharge and reducing post-procedural bed rest, LockeT offers a compelling economic case for hospitals seeking to optimize resource utilization.
• International Expansion: Building on its CE Mark approval, the company continues to penetrate the European closure market where the economic advantages of LockeT are compelling.
  
  

About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.

About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words.  These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.

The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

CONTACTS:

Investor Relations
973-691-2000
IR@catheterprecision.com

# # #

FAQ

What hospital approvals did Catheter Precision (VTAK) announce on February 4, 2026?

Catheter Precision announced new evaluations and approvals at multiple high-volume U.S. centers for LockeT. According to the company, evaluations include Johns Hopkins, University of Michigan, Beth Israel Boston, Northside Atlanta, and Scripps Southern California.

How does Catheter Precision describe LockeT's effect on hospital workflows and costs for VTAK investors?

LockeT is said to streamline workflows and enable same-day discharge, reducing post-procedural bed rest. According to the company, these features support faster staff onboarding and a compelling economic case for hospitals seeking resource optimization.

What did Catheter Precision report about revenue and Q1 2026 adoption expectations for VTAK?

The company reported its highest recorded revenue for January and expects robust product adoption in Q1 2026. According to the company, a strong pipeline of hospital evaluations should support transitions to permanent adoption.

Is Catheter Precision expanding internationally for LockeT and what approvals support that expansion?

Yes, Catheter Precision is expanding internationally and is building on CE Mark approval to enter European markets. According to the company, CE Mark activity underpins continued penetration where LockeT's economic advantages are compelling.

What clinical or operational evidence did Catheter Precision cite to support LockeT adoption for VTAK shareholders?

The company cited successful clinical outcomes and rapid staff onboarding at major institutions as adoption drivers. According to the company, those evaluations are precursors to long-term purchasing agreements and broader network adoption.